China SXT Pharmaceuticals Inc. Class A Ordinary Shares (SXTC)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunt: price is what you pay, value is what you get. China SXT Pharmaceuticals is a $2.0 million market-cap maker of traditional Chinese medicine pieces with only 56 employees. At the 2026-10-13 close of $0.08, the FairStock-calculated P/E and P/B are both 0.00, which tells me there is no positive earnings or book-value anchor to work with. The business quality looks poor: FairStock calculations show ROE of -27.49% and ROCE of -15.78%, and the Piotroski F-Score is 2/9. The Altman Z-Score of -0.10 sits in distress territory. The only balance-sheet positive is a low D/E of 0.04. A durable moat? I see none. It sells commodity-like TCMP products in a competitive Chinese market, and its tiny scale gives it little pricing power. Growth is opaque: revenue and profit growth are listed as N/A, and the computed Lynch category is none because there are only 0 years of filed annual results, versus the 3 needed. The 52-week range of $0.04 to $1,047 is a warning that the share price has been wildly unstable, with beta at 1.84. On valuation, a $2.0 million market cap may look cheap, but cheapness without earning power or reliable filings is not a margin of safety; it may be a value trap. Graham wanted demonstrated earnings and assets, and Buffett wants durable economics. Neither is evident here. The numbers do not support calling this a sound investment. It is a speculative micro-cap with negative returns and weak financial scores. This would not meet my criteria.

In plain English: China SXT Pharmaceuticals makes and sells traditional Chinese medicine pieces in China. The business looks weak: it is very small, losing money, and has weak financial health scores. At $0.08 a share, the price looks very low, but the numbers do not show a clear bargain because there is little profit and little filed history.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer